Can-Fite Biopharma Ltd.

www.canfite.com

High-Tech Company
Public Company

(TASE: CANF), (NYSE-MKT: CANF)

TECH VERTICALS

Cancer, Life Sciences, Medical Cannabis, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	2000
Number of Employees	13
Reg. Number:	abCDe

DESCRIPTION

Can·Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development which address oncology, inflammatory, and metabolic diseases.

TECHNOLOGY

Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer and other pathological body cells whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The Company's compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects.

Products and Phases

Product	Phase
Piclidenoson (CF101)	Phase III
Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. The activity of Piclidenoson as an anti-inflammatory agent has been tested in a number of different experimental models including adjuvant and collagen induced arthritis, osteoarthritis and inflammatory bowel disease. In all models tested, Piclidenoson induced a robust anti-inflammatory effect measured by clinical and histological disease scores.
Namodenoson (CF102)	Phase III
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson has a potent anti-cancer effect, particularly against hepatocellular and pancreatic carcinoma, as well as anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation and MASH.
CF602	Pre-Clinical
CF602 is a novel A3AR allosteric modulator that CF602 increases eNOS and VEGF in cavernosal endothelial cells. Repeated doses of CF602 over five days of treatment showed it partly reversed damage in the smooth muscle. The activity of CF602 was examined in an erectile dysfunction rat model. A single dose of CF602 showed full recovery in erectile function.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Biotech and Pharmaceutical companies, Healthcare industry, Healthcare providers.

	BUSINESS MODEL
	B2B

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
8EC967EA-1F7A-E111-AC59-00155D32A403		Can-Fite Biopharma Ltd.
61AB3914-207A-E111-AC59-00155D32A403	Spin-off	OphthaliX Inc.	Can-Fite Biopharma Ltd.	Acquired/Merged

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Accounting Firm

CONTACT INFO

Expand / Collapse All

Main Address: Petach Tikva, Israel

Address	10 Bareket St., Kiryat Matalon
POB	7537
City	Petach Tikva
Country	Israel
Zip	4951778

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Motti Farbstein	CEO & CFO	OphthaliX (Manager, Corporate Affairs)
Prof. Pnina Fishman	CSO & Co-Founder	OphthaliX (Interim CEO)
Dr. Sari Fishman-Furman	VP, Business Development	OphthaliX (Director of Business Development)
Dr. Ilan Cohn	Co-Founder	Reinhold Cohn Group (Senior Partner)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	CSO & Co-Founder, Can-Fite
abC Defghij	Board Member	Co-Founder, Can-Fite Biopharma
abC Defghij	Board Member	Owner at Maanit-Goldman Management & Investments
abC Defghij	Board Member	CEO & Founder, Shizim Group
abC Defghij	Board Member	CEO, B. Gaon Holdings Ltd.
abC Defghij	Independent Director	Former VP & Director Pharmaceutical R&D Division, Recordati

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Jul. 29, 2025	Seventeenth Public Offering	NYSE-MKT	abCDe	abCDe	Shares and short term warrants. The potential additional gross proceeds to the company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $10m.
Apr. 14, 2025	Sixteenth Public Offering	NYSE-MKT	abCDe	abCDe	Registered Direct Offering
Jan. 11, 2023	Fifteenth Public Offering	NYSE	abCDe	abCDe
Jul. 06, 2020	Fourteenth Public Offering		abCDe	abCDe	Registered Direct Offering.
Jun. 10, 2020	Thirteenth Public Offering		abCDe	abCDe	Registered Direct Offering.
Feb. 11, 2020	Twelfth Public Offering	NYSE-MKT	abCDe	abCDe
May. 22, 2019	Eleventh Public Offering	NYSE-MKT	abCDe	abCDe
Apr. 04, 2019	Tenth Public Offering	NYSE-MKT	abCDe	abCDe	Registered Direct Offering
Jan. 20, 2017	Ninth Public Offering	NYSE-MKT	abCDe	abCDe	Registered Direct Offering
Sep. 20, 2015	Eighth Public Offering	NYSE-MKT	abCDe	abCDe	Registered Direct Offering
Dec. 02, 2014	Seventh Public Offering	NYSE-MKT	abCDe	abCDe	Registered Direct Offering of ADS
Nov. 15, 2013	Listing	NYSE-MKT	abCDe	abCDe	Listing by ADRs.
Oct. 24, 2013	Sixth Public Offering	OTCQB	abCDe	abCDe
Feb. 05, 2013	Fifth Public Offering	TASE	abCDe	abCDe
Oct. 04, 2012	Listing	OTCQB	abCDe	abCDe	Through ADR.
Oct. 28, 2010	Fourth Public Offering	TASE	abCDe	abCDe
Jul. 07, 2009	Third Public Offering	TASE	abCDe	abCDe	Rights issue, in two series.
May. 17, 2006	Second Public Offering	TASE	abCDe	abCDe	Convertible Debentures
Sep. 30, 2005	IPO	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Mar. 04, 2026

Initial Revenues

abCDe

PIPE

Nov. 24, 2023

Initial Revenues

abCDe

PIPE

Jan. 11, 2023

Initial Revenues

abCDe

PIPE

Dec. 20, 2021

Initial Revenues

abCDe

PIPE

Mar. 10, 2014

Initial Revenues

abCDe

PIPE

Dec. 24, 2008

R&D

abCDe

PIPE

Mar. 08, 2007

R&D

abCDe

PIPE

Jan. 14, 2007

R&D

abCDe

Fourth Round

Jun. 01, 2005

R&D

abCDe

Third Round

Jun. 01, 2004

R&D

abCDe

Second Round - Extended

Jun. 11, 2003

R&D

abCDe

Second Round - Extended

Jan. 17, 2003

R&D

abCDe

Second Round - Extended

Dec. 01, 2002

R&D

abCDe

Second Round

Jul. 03, 2002

R&D

abCDe

First Round

Mar. 04, 2001

R&D

abCDe

Seed

Oct. 01, 2000

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

May. 22, 2012

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Oct. 01, 2000

Contributor	Type	Amount	Remarks
abC Defghij	Technology Transfer Company	abCDe	Holds 4.2% of the company

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

OphthaliX

Biomed

Other

16/11/2011

$0.5m

N/A

Undisclosed institutional investors and Can-Fite BioPharma Ltd. (Can-Fite is Denali’s main shareholder holding approximately 82%).

Last Updated:	abCDe
IVC Number:	abCDe